Non-Alcoholic Fatty Liver (NAFL)

This six-month human clinical trial showed that Basis, at the recommended dose, reduced several markers of liver inflammation in healthy adults with fatty liver. The results, published in Hepatology, also further confirmed that Basis is safe and well tolerated and supports liver function in healthy individuals. Publication here. ClinicalTrials.gov Identifier: NCT03513523

Related Articles

  • TIME-ZZZ

    The Translational Initiative to Map Epigenetics in Sleep (TIME-ZZZ) is a longitudinal, prospective research study that aims to advance our understanding of the interplay between sleep, mental health, and biological aging. All Index users are eligible to enroll. The study can be found on www.clinicaltrials.gov under the identifier NCT06333301.

  • NADAPT

    Initiated at Haukeland University Hospital, this human clinical trial is evaluating the efficacy of NAD replenishment therapy with NR in delaying disability progression and amelioration of symptoms in patients with atypical parkinsonian syndromes. The estimated study completion date is December 2028. ClinicalTrials.gov Identifier: NCT06162013

  • Progressive MS

    Initiated at Haukeland University Hospital, this human clinical trial is evaluating the safety and efficacy of NR on slowing disability progression in patients with progressive multiple sclerosis. The estimated study completion date is December 2027. ClinicalTrials.gov Identifier: NCT05740722